Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Harmony Biosciences

Harmony Biosciences Crashes On Surprise Rejection For Bread-And-Butter Drug

Harmony Sciences shares plunged Wednesday after the FDA rejected its bread-and-butter drug as a treatment for a daytime sleepiness condition.

Investors Business Daily

Stocks With Rising Relative Price Strength: Harmony Biosciences

Harmony Biosciences sees its Relative Strength Rating enter the 80-plus level.

Investors Business Daily

Harmony Biosciences Stock Scores 80-Plus RS Rating

Harmony Biosciences sees its Relative Strength Rating move into the 80-plus level.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Harmony Biosciences Scores Relative Strength Rating Upgrade; Hits Key Threshold

Harmony Biosciences sees its Relative Strength Rating enter the 80-plus level.

Investors Business Daily

Harmony Biosciences Scores Relative Strength Rating Upgrade; Hits Key Threshold

Harmony Biosciences shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 67 to 80.

Investors Business Daily

Harmony Biosciences Earns Relative Strength Rating Upgrade

A Relative Strength Rating upgrade for Harmony Biosciences shows improving technical performance. Will it continue?

Investors Business Daily

Harmony Biosciences Shows Rising Price Performance With Jump To 91 RS Rating

A Relative Strength Rating upgrade for Harmony Biosciences shows improving technical performance.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Harmony Bio, The No. 1 Biotech Stock, Surges On Its 'High Quality' Beat

Harmony Biosciences stock jumped Tuesday on the biotech company's "high-quality" third-quarter beat on the back of its narcolepsy drug.

Investors Business Daily

Harmony Biosciences, The No. 3 Biotech, Just Topped Forecasts; But Concerns Persist

Harmony Biosciences beat quarterly expectations Tuesday, but the biotech stock crumbled on a barrage of commercial concerns.

Investors Business Daily

Why IBD 50 Stock Harmony Biosciences Surged Well Above A Buy Zone

Harmony crushed third-quarter forecasts and unveiled promising results for its narcolepsy drug — leading the biotech stock to surge Tuesday.

Investors Business Daily

IBD 50 Stocks To Watch: Health Stock Hits Buy Point Ahead Of Earnings

Harmony Biosciences beat EPS and sales expectations last quarter, sending shares up over 12%.

Investors Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2022

Upgrades

Benzinga

Harmony Biosciences Makes Leap Out Of Buy Zone After Narcolepsy Drug Drives Beat

Harmony Biosciences crushed expectations Tuesday, citing a growing number of narcolepsy patients on its drug, and the biotech stock surged.

Investors Business Daily

Medical Sector Leads New Buys By Top Funds While Big Mac Joins Big Oil

As tech titans like Apple and Nvidia get shunned again, the best mutual funds focus on Big Pharma and biotech stocks.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Major Stock Indexes are Mixed; Health Care Stocks Lead, But These Leaders Break Down

Health care and biotech stocks are showing strength.

Investors Business Daily

Biotech Stock United Therapeutics Revives Breakout, Retakes Buy Zone

Biotech stock United Therapeutics joins peers Vertex and Harmony Biosciences on the Breakout Stocks Index as it reenters a buy zone.

Investors Business Daily

Dow Jones Futures Fall After Stocks Rally On Big Fed Rate Hike; What To Do Now

Futures tumbled, threatening to wipe out Wednesday's market rally in a day two reaction to the biggest Fed rate hike since 1994.

Benzinga

Harmony Biosciences Earnings Perspective: Return On Capital Employed

Pulled from Benzinga Pro data, Harmony Biosciences (NASDAQ:HRMY) posted Q1 earnings of $21.48 million, an increase from Q4 of 5.41%. Sales dropped to $85.31 million, a 6.47% decrease between quarters.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Harmony Biosciences: Q1 Earnings Insights

Harmony Biosciences (NASDAQ:HRMY) reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

Benzinga

Harmony Biosciences Q1 2022 Earnings Conference Call On May 3, 2022 At 08:30 AM ET

Harmony Biosciences (NASDAQ:HRMY) will host a conference call at 08:30 AM ET on May 3, 2022, to discuss Q1 2022 earnings results.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022

Upgrades

Investors Business Daily

IBD 50 Stocks To Watch: Biotech Stock Harmony Biosciences Nears Buy Point Of New Base

Biotech stock Harmony Biosciences is near the buy point of a new cup base, putting it among growth stocks to watch.

Benzinga

Looking Into Harmony Biosciences's Return On Capital Employed

According to Benzinga Pro, during Q4, Harmony Biosciences (NASDAQ:HRMY) earned $22.71 million, a 336.11% increase from the preceding quarter. Harmony Biosciences also posted a total of $91.21 million in sales, a 12.98% increase since Q3.

Benzinga

Harmony Biosciences: Q4 Earnings Insights

Harmony Biosciences (NASDAQ:HRMY) reported its Q4 earnings results on Monday, February 28, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.